Specialty Pharmacy

Engineered chimeric antigen receptor T-cells differentiate between cancerous and normal cells.

Concerns raised over treatment that fights fungal infections in lung transplant patients.

Research may lead to new combination therapies that attack different parts of cancer cells.

Pharmacists in California could soon be required to provide prescription drug labels in 5 languages besides English under a law unanimously passed by state lawmakers.

Exclusively breastfeeding may diminish MS relapse in the first 6 months after giving birth.

Mutations that affect splicing in oncogenes may facilitate tumor progression.

Researchers target cell division to prevent the growth and spread of cancer.

Researchers target new opportunities for preventive interventions.

Improvements can be made to provide procedure-specific national benchmarks for postsurgical outcomes.

All non-expired drugs produced for sterile use by Alabama-based compounder Medistat RX have been recalled due to potential contamination, the FDA is warning pharmacists.

Employers with onsite pharmacies are seeing a return on investment in the form of increased medication adherence among their health plan members.

Researchers seek to determine how compound from chili peppers kills prostate cancer cells.

Study finds patients with low-risk prostate cancers be monitored in an active surveillance program.

Top developments from the last week in cancer treatment.

Researchers evaluate how DNA viruses work and how they can be stopped.

Opinions in the health care community vary on medical marijuana.

Findings could boost the efficacy of immunotherapy drugs.

Treatments skipped due to cost are at their lowest percentage since 1999.

Clinical outcomes expected to continue improving as new treatments arrive.

Top stories of the week on Specialty Pharmacy Times.

Multiple sclerosis advocate discusses the difficulties patients face during treatment.

New approach may combine with existing medications to improve survival.

Test may identify and treat premalignant pancreatic lesions.

Use of diabetes therapy may increase the risk of bone fracture.

Humira approved for the treatment of moderate to severe hidradenitis suppurativa.

Ixazomib is the first investigational oral proteasome inhibitor for relapsed and/or refractory multiple myeloma.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.

New method may improve treatment for a number of diseases.